While statins are one of the most widely prescribed medications worldwide, concerns about the drugs’ associations with dysglycemia and new-onset diabetes still remain.
In a study presented at the American Diabetes Association’s 79th Scientific Sessions, researchers aimed to investigate the effects of a certain sodium-glucose co-transporter-2 inhibitor on kidney disease...
While previous studies have suggested that lower blood 25-hydroxyvitamin D levels are associated with the risk of type 2 diabetes, whether supplementation could affect this association is still unknown. ...
In a new study, CDC scientists evaluated trends in the incidence and prevalence of diagnosed type 1 and type 2 diabetes from 1980 to 2017. Some findings were encouraging, while others highlight areas of...
Because of the common nature of non-alcoholic fatty liver disease and the chance of progression to non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma, researchers sought to estimate the...
New guidelines from an international group of methodologists, general practitioners, internists, endocrinologists, and patient partners with subclinical hypothyroidism could, if implemented,...
Previous research has indicated that use of sodium-glucose cotransporter-2 inhibitors could be associated with a rare urologic necrotizing infection. In a recent analysis, the FDA sought to further examine...
While metformin is the most common treatment of choice in children with type 2 diabetes, early loss of glycemic control has been observed with metformin monotherapy.
Although type 2 diabetes is the leading cause of kidney failure, few long-term treatment options for renoprotection in these patients are currently available.
The American Diabetes Association has updated its 2019 standards of care for diabetes focusing on the improvement of cardiovascular and renal health in individuals with diabetes.
